We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GLP-1 Weight Loss Drugs Shift Eating Habits in Americans

Person holding a GLP-1 injection pen, preparing for administration.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

The rising use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss is changing how Americans eat, with implications already visible in the food and beverage industry. A new study from the Arkansas Agricultural Experiment Station reports that these medications are linked to a decrease in consumption of processed foods, sugar-sweetened drinks and other calorie-dense items.


GLP-1 receptor agonist

A type of drug that mimics the glucagon-like peptide-1 hormone. It stimulates insulin secretion and reduces appetite, helping to control blood sugar and support weight loss.

“We’ve already seen a shift in how food companies market their products. For packaged food companies, stock prices were going down while the stock prices for pharmaceutical companies that make these medications were going up.


Dr. Brandon McFadden

GLP-1s such as semaglutide and tirzepatide – found in drugs like Ozempic, Wegovy, Mounjaro and Zepbound  were originally developed to manage blood sugar in people with type 2 diabetes. They mimic the GLP-1 hormone that regulates insulin secretion and appetite. Their ability to reduce hunger has led to their approval by the US Food and Drug Administration (FDA) for weight loss in people with a body mass index (BMI) of 30 or more, or 27 with a weight-related condition.


Body mass index (BMI)

A measurement that uses height and weight to estimate body fat. A BMI of 30 or more is considered obese; 25 to 29.9 is considered overweight.

Semaglutide and tirzepatide

Pharmaceutical compounds used in medications like Ozempic and Mounjaro. They act on the GLP-1 receptor to manage blood sugar and reduce appetite.


Between 2020 and 2022, usage of these drugs increased by 300%. Tens of thousands of new users are estimated to be starting treatment each week, with about half of the US population estimated to meet eligibility criteria.

Changes in eating patterns

The Arkansas study surveyed 1,955 people, including current and former users of GLP-1s, as well as individuals who planned to take them or had no intention of doing so. Researchers found that those currently or previously taking GLP-1s reported consuming fewer processed foods, sugary beverages, refined grains and red meat.


About 70% more respondents reported a decrease in processed food consumption than an increase. Soda, refined grains and beef also showed net reductions in consumption, with a similar pattern seen for pork, alcohol, dairy milk, fruit juice and starchy vegetables. However, some categories such as chicken, fish, coffee and plant-based products showed more modest changes.


Despite these reductions, many participants still reported desiring high-fat or high-sugar foods. The study found that only a few categories – including fruit, leafy greens and water – showed an overall increase in both consumption and desire.

Industry response

The food and beverage industry has begun responding to these shifts. For instance, some brands are introducing products aimed specifically at GLP-1 users. A notable example is a “meal in one” bar designed for this audience. Chains such as Smoothie King have created new menu sections labeled “GLP-1 Support.”


According to the study, this pattern in consumer behavior may create new challenges and opportunities for companies. Packaged food companies, facing lower demand for their traditional products, could look to diversify offerings to include options better aligned with the preferences of GLP-1 users.


The researchers suggest that understanding these behavioral shifts could help companies develop marketing strategies, product offerings and guidance for consumers using weight loss medications. A follow-up study will examine user-reported side effects.


Reference: Dilley A, Adhikari S, Silwal P, L. Lusk Jayson, McFadden BR. Characteristics and food consumption for current, previous, and potential consumers of GLP-1 s. Food Quality Preference. 2025;129:105507. doi: 10.1016/j.foodqual.2025.105507


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.


This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.